Retinoblastoma. Part 2. Treatment strategies for intraocular retinoblastoma

Q4 Medicine
S. V. Ivanova, S. Kuleva, N. N. Sadovnikova, M. I. Komissarov, M. N. Chistyakova, A. Khokhlova, N. Shchegoleva
{"title":"Retinoblastoma. Part 2. Treatment strategies for intraocular retinoblastoma","authors":"S. V. Ivanova, S. Kuleva, N. N. Sadovnikova, M. I. Komissarov, M. N. Chistyakova, A. Khokhlova, N. Shchegoleva","doi":"10.32364/2311-7729-2020-20-4-197-203","DOIUrl":null,"url":null,"abstract":"Retinoblastoma is one of the most common retinal tumors in young children. Current early diagnostic and treatment strategies focus on the possibility to implement eye-preserving therapies. The 5-year overall survival for children with retinoblastoma is now 100%. First-line eye removal is recommended in extensive intraocular seeding and poor visual prognosis. The volume of adjuvant therapy is based on the histological risk factors for disease progression. This paper discusses the algorithms to determine risk factors and further systemic treatment strategy in several large study groups. Eye and even vision preservation is now possible in at least 65–75% of retinoblastoma patients. The paper also describes in detail the methods of locally administering chemotherapy which are considered eye-preserving treatment options, i.e., selective intra-arterial chemotherapy and intravitreal chemotherapy. Various physical methods of eye-preserving treatment which underwent significant development over the past decade are highlighted. In conclusion, the authors emphasize that retinoblastoma survivors, their siblings and offspring should be carefully monitored.Keywords: children, retinoblastoma, enucleation, polychemotherapy, selective intra-arterial chemotherapy, intravitreal chemotherapy, laser photocoagulation, transpupillary thermotherapy, cryotherapy, brachytherapy, monitoring.For citation: Ivanova S.V., Kuleva S.A., Sadovnikova N.N. et al. Retinoblastoma. Part 2. Treatment strategies for intraocular retinoblastoma. Russian Journal of Clinical Ophthalmology. 2020;20(4):197–203. DOI: 10.32364/2311-7729-2020-20-4-197-203.","PeriodicalId":36455,"journal":{"name":"Russian Journal of Clinical Ophthalmology","volume":"35 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Russian Journal of Clinical Ophthalmology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.32364/2311-7729-2020-20-4-197-203","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Retinoblastoma is one of the most common retinal tumors in young children. Current early diagnostic and treatment strategies focus on the possibility to implement eye-preserving therapies. The 5-year overall survival for children with retinoblastoma is now 100%. First-line eye removal is recommended in extensive intraocular seeding and poor visual prognosis. The volume of adjuvant therapy is based on the histological risk factors for disease progression. This paper discusses the algorithms to determine risk factors and further systemic treatment strategy in several large study groups. Eye and even vision preservation is now possible in at least 65–75% of retinoblastoma patients. The paper also describes in detail the methods of locally administering chemotherapy which are considered eye-preserving treatment options, i.e., selective intra-arterial chemotherapy and intravitreal chemotherapy. Various physical methods of eye-preserving treatment which underwent significant development over the past decade are highlighted. In conclusion, the authors emphasize that retinoblastoma survivors, their siblings and offspring should be carefully monitored.Keywords: children, retinoblastoma, enucleation, polychemotherapy, selective intra-arterial chemotherapy, intravitreal chemotherapy, laser photocoagulation, transpupillary thermotherapy, cryotherapy, brachytherapy, monitoring.For citation: Ivanova S.V., Kuleva S.A., Sadovnikova N.N. et al. Retinoblastoma. Part 2. Treatment strategies for intraocular retinoblastoma. Russian Journal of Clinical Ophthalmology. 2020;20(4):197–203. DOI: 10.32364/2311-7729-2020-20-4-197-203.
视网膜母细胞瘤。第2部分。眼内视网膜母细胞瘤的治疗策略
视网膜母细胞瘤是幼童视网膜最常见的肿瘤之一。目前的早期诊断和治疗策略侧重于实施保眼疗法的可能性。儿童视网膜母细胞瘤的5年总体生存率现在是100%。在广泛的眼内播种和视力预后差的情况下,推荐一线眼摘除。辅助治疗的量是基于疾病进展的组织学危险因素。本文讨论了在几个大型研究小组中确定风险因素和进一步系统治疗策略的算法。现在至少有65-75%的视网膜母细胞瘤患者可以保留眼睛甚至视力。本文还详细介绍了局部给药的保眼治疗方法,即选择性动脉内化疗和玻璃体内化疗。重点介绍了近十年来取得重大发展的各种保眼物理治疗方法。总之,作者强调,视网膜母细胞瘤幸存者、他们的兄弟姐妹和后代应该仔细监测。关键词:儿童,视网膜母细胞瘤,去核,多重化疗,选择性动脉内化疗,玻璃体内化疗,激光光凝,上突热疗,冷冻治疗,近距离放疗,监测。引证:Ivanova s.v., Kuleva s.a., Sadovnikova N.N.等。视网膜母细胞瘤。第2部分。眼内视网膜母细胞瘤的治疗策略。俄罗斯临床眼科杂志,2020;20(4):197-203。DOI: 10.32364 / 2311-7729-2020-20-4-197-203。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
0.60
自引率
0.00%
发文量
21
审稿时长
20 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信